Neurology Research International

Neurology Research International / 2011 / Article

Review Article | Open Access

Volume 2011 |Article ID 740505 | 22 pages | https://doi.org/10.1155/2011/740505

Symptomatic Therapy and Rehabilitation in Primary Progressive Multiple Sclerosis

Academic Editor: Peter van den Bergh
Received19 May 2011
Accepted13 Jul 2011
Published17 Oct 2011

Abstract

Multiple sclerosis (MS) is an autoimmune inflammatory demyelinating disease of the central nervous system and a major cause of chronic neurological disability in young adults. Primary progressive MS (PPMS) constitutes about 10% of cases, and is characterized by a steady decline in function with no acute attacks. The rate of deterioration from disease onset is more rapid than relapsing remitting and secondary progressive MS types. Multiple system involvement at onset and rapid early progression have a worse prognosis. PPMS can cause significant disability and impact on quality of life. Recent studies are biased in favour of relapsing remitting patients as treatment is now available for them and they are more likely to be seen at MS clinics. Since prognosis for PPMS is worse than other types of MS, the focus of rehabilitation is on managing disability and enhancing participation, and application of a “neuropalliative” approach as the disease progresses. This chapter presents the symptomatic treatment and rehabilitation for persons with MS, including PPMS. A multidisciplinary approach optimizes the intermediate and long-term medical, psychological and social outcomes in this population. Restoration and maintenance of functional independence and societal reintegration, and issues relating to quality of life are addressed in rehabilitation processes.

1. Background

Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS) affecting about 2.5 million persons’ worldwide [1]. It is the commonest cause of chronic neurological disability in young adults. MS is complex and the exact pathogenesis is unclear. The various disease courses in persons with MS (pwMS) are shown in Box 1. One recent survey of 878 persons with primary progressive MS (PPMS) [2] were found to have a shorter median time to death from onset and a higher relative risk of dying despite the fact that persons with PPMS live for years with many disabilities that can cause limitation in function and restriction in participation and impact quality of life (QoL) [3].

The natural history of PPMS is less well known compared with other MS disease courses. Primary progressive MS occurs in approximately 10% of pwMS and is primarily progressive from onset. Approximately <5% of pwMS may present with a progressive course although these patients also experience occasional attacks, the progressive relapsing MS type (PRMS) (see Box 1). The diagnostic criteria for PPMS are shown in Table 1. It is thought to be different genetically from the relapsing remitting MS (RRMS) and in MRI behaviour from secondary progressive MS type (SPMS) [4, 5]. In PPMS, the paucity of MRI detectable disease activity is in contrast with the observed accumulation of irreversible disability [6]. Quantitative MRI studies [7] have highlighted the role of brain tissue damage outside T2 visible lesions in the pathophysiology of PPMS. Kutzelnigget al. [8] showed that diffuse white matter injury and cortical demyelination were hallmarks of progressive MS, occurring on a background of a global “low burning” inflammatory response with focal lesion load. The contribution of cord damage to the severity and evolution of PPMS has also been evident in several MRI studies [9, 10].


Clinical (Attacks)Objective lesionsAdditional requirements to make a diagnosis

Two or moreTwo or more, or objective clinical evidence of one lesion with reasonable historical evidence of a prior attackNone

Two or moreOneDissemination in space, demonstrated by:
one or more T2 lesion in at least 2 of 4 MS-typical regions of the CNS (periventricular, juxtacortical, infratentorial, or spinal cord) or await a further clinical attack implicating a different CNS site

OneTwo or moreDissemination in time, demonstrated by:
simultaneous presence of asymptomatic gadolinium-enhancing and nonenhancing lesions at any time; or A new T2 and/or gadolinium-enhancing lesion(s) on follow-up MRI, irrespective of its timing with reference to a baseline scan or await a second clinical attack

One (clinically isolated syndrome)OneDissemination in space and time, demonstrated by:
for DIS:
one or more T2 lesion in at least 2 of 4 MS-typical regions of the CNS (periventricular, juxtacortical, infratentorial, or spinal cord) or await a second clinical attack implicating a different CNS site and For DIT:
simultaneous presence of asymptomatic gadolinium-enhancing and nonenhancing lesions at any time or a new T2 and/or gadolinium-enhancing lesion(s) on follow-up MRI, irrespective of its timing with reference to a baseline scan or await a second clinical attack

Insidious neurological progression suggestive of MS (PPMS)One year of disease progression (retrospectively or prospectively determined) plus 2 of 3 of the following criteria:
(1) evidence for DIS in the brain based on one or more T2 lesions in the MS-characteristic (periventricular, juxtacortical, or infratentorial) regions,
(2) evidence for DIS in the spinal cord based on tow or more T2 lesions in the cord
(3) positive CSF (isoelectric focusing evidence of oligoclonal bands and/or elevated IgG index)

MS: multiple sclerosis; CNS: central nervous system; MRI: magnetic resonance imaging; DIS: dissemination in space; DIT: dissemination in time; PPMS: primary progressive multiple sclerosis; CSF: cerebrospinal fluid; IgG: immunoglobulin G. (Adapted from Polman et al. [12].)

The overall female preponderance in MS is less applicable to PPMS. The rate of deterioration from disease onset in PPMS is more rapid, with higher relative mortality than other MS types [13]. Those with shorter time from onset to disability and those with involvement of three or more neurological symptoms at onset have a worse prognosis [14]. However prognosis in PPMS is not dependent on age, gender, or type of neurological system involvement at onset. A minority of people with PPMS can have a distinct relapse even decades after onset of progressive deterioration [14].

Recent nonpopulation-based studies are biased towards RRMS as treatment is now available for reducing the number of relapses and delaying disease progression, so they are more likely to be reviewed at MS clinics. All suggested drug treatments for PPMS are empiric as there is no convincing trial evidence of effectiveness for disease modifying therapy [17]. An individual with PPMS, therefore, has limited drug therapy options and may benefit from a symptomatic and supportive rehabilitation approach aimed at reducing symptoms and limitations at the level of activity and participation.

Studies of pwMS have identified a range of impairments, limitations in activity (disability), and restriction in participation using the World Health Organization’s International Classification of Functioning, Health, and Disability (ICF) Figure 1 [15, 18, 19]. These ICF domains have complex interactions and need evaluation and management through holistic interventions, which include personal and environmental factors. Recent MS expert consensus identified and recommended the “Core” set (minimum data set) of ICF categories for pwMS for comprehensive multidisciplinary assessments in the domains of body function, body structure, activities, and participation and environmental factors [18] (Tables 23). Much of the clinical focus has traditionally been on the physical aspects of MS but improved understanding of MS indicates involvement of multiple systems (cognition, memory, and emotional control). The combined effect of these impairments in a pwMS leads to greater disability than the sum of the individual impairments together. This may explain why some pwMS may not perform as well as expected [20].


ICF codeICF category title

Body function
B122global psychosocial functions
B130energy and drive functions
B144memory function
B147psychomotor function
B126temperament and personality functions
B152emotional functions
B164higher level cognitive functions
B140attention function
B160thought functions
B114orientation functions
B210seeing function
B265touch function
B260proprioceptive function
B280sensation of pain
B235vestibular functions
B320articulation functions
B330fluency and rhythm of speech functions
B310voice functions
B455exercise tolerance functions
B435immunological system functions
B525defecation function
B640sexual functions
B620urination functions
B760control of voluntary movement functions
B750motor reflex functions
B730muscle power functions
B735muscle tone functions
B755involuntary movement reaction functions
B770gait pattern functions
B710mobility of joint functions
B780sensations related to muscle and movement functions
B715stability of joint functions
Body structure
S110structure of brain
S120structures spinal cord and related
S610structure of urinary system
S720dstructure of shoulder region
S730structure of upper extremity
S750structure of lower extremity
S760structure of trunk

(Adapted from Khan and Pallant [18].)

ICF codeICF category title

Activities and participation
D160focusing attention
D172calculating
D175solving problems
D220undertaking multiple tasks
D240handling stress and other psychological demands
D163thinking
D166reading
D177making decisions
D230carrying out daily routine
D210undertaking a single task
D330speaking
D350conversation
D355discussion
D345writing messages
D315communicating with-receiving-nonverbal messages
D310communicating with-receiving-spoken messages
D360using communication devices and techniques
D335producing nonverbal messages
D325communicating with-receiving-written messages
D415maintaining a body position
D420transferring oneself
D445hand and arm use
D450walking
D455moving around
D410changing basic body position
D430lifting and carrying objects
D440fine hand use
D460moving around in different locations
D456moving around using equipment
D470using transportation
D475driving
D510washing oneself
D530toileting
D540dressing
D550eating
D520caring for body parts
D560drinking
D570looking after one’s health
D630preparing meals
D640doing housework
D650caring for household objects
D620acquisition of goods and services
D770intimate relationships
D710basic interpersonal interactions
D720complex interpersonal interactions
D740formal relationships
D760family relationships
D750informal social relationships
D850remunerative employment
D845acquiring keeping and terminating a job
D870economic self sufficiency
D825vocational training
D855nonremunerative employment
D860basic economic transactions
D920recreation and leisure
D910community life
D930religion and spirituality
Environmental Factors
E120products or technology for personal indoor/outdoor mobility and transportation
E135products and technology for employment
E115products or technology for personal use in daily living
E125products and technology for communication
E130products and technology for education
E155design, construction, building products, and technology of buildings for private use
E150design, construction, building products, and technology of buildings for public use
E110products or substances for personal consumption
E165assets
E225climate
E210physical geography
E310immediate family
E320friends
E355health professionals
E340personal care providers and personal assistants
E360health related professionals
E325acquaintances, peers colleagues, neighbours, and community members
E330people in positions of authority
E315extended family
E410individual attitudes of immediate family members
E420individual attitudes of friends
E450individual attitudes of health professionals
E455individual attitudes of health related professionals
E425individual attitudes of acquaintances, peers colleagues, neighbours, and community members
E440individual attitudes of personal care providers and personal assistants
E460societal attitudes
E430individual attitudes of people in positions of authority
E570social security services, systems, and policies
E575general social support services, systems, and policies
E525housing services, systems, and policies
E540transportation services, systems, and policies
E590labour and employment services, systems, and policies
E530utilities services, systems, and policies
E510services, systems and policies for the production of consumer goods
E515architecture and construction services, systems, and policies
E580health services, systems, and policies

(Adapted from Khan and Pallant [18].)

2. Rehabilitation

Rehabilitation is defined as a problem solving educational process aimed at reducing disability and limitation in participation [21]. Rehabilitation interventions comprise expert MD assessments evaluated through appropriate outcome measures [22] using functional goal-oriented approaches such as clinical pathways [23] to target patient priorities [24]. Goal setting is an integral part of rehabilitation, as it encourages participants to set their own goals and priorities, and supports team communication and coordination. The key subcomponents and phases of the rehabilitation process [16] are shown in Boxes 2 and 3.

Existing clinical guidelines and frameworks [26, 27] for PPMS recommend comprehensive, flexible coordinated multidisciplinary (MD) care and appropriate followup, education, and support for patients and carers to address the limitations in activity and participation levels. Key issues for those severely affected include respite, community and/or long-term care, and community mobility. Early referral for rehabilitation enables strategies to restore recent functional deterioration [26]. In those severely affected, rehabilitation input can provide a modified environment and adaptive equipment to restore some functional independence. Caregiver education and support can reduce the burden of care. Rehabilitation can address QoL issues and direct care with other health professionals [28]. Importantly, “crisis management” should be avoided, planned management of disability and deficits should be anticipated (over time), and appropriate mechanisms that accommodate and facilitate functional independence provided. Some of the challenges to MS rehabilitation are shown in Box 4.

3. Evidence for MS Rehabilitation

A recent systematic review supports the effectiveness of MD rehabilitation programs in inpatient and ambulatory settings in terms of improvements in activity (disability) and participation [29]. Although there is evidence for some unidisciplinary rehabilitation interventions for pwMS, such as physical therapy [30], the evidence for others-occupational therapy [31] and psychological therapies [32] is less compelling. There is reasonable evidence to support cognitive behaviour approaches for depression in helping people adjust to, and cope with, having MS [33]. A recent randomized controlled trial showed the duration of benefit of rehabilitation in reducing disability persists for about 12 months [34] but not the positive effects on QoL and emotional well-being. Effects on QoL are often difficult to quantify in chronic conditions because of “response shift” or the change in internal values, or conceptualization of QoL, so that pwMS may reassess their perceived limitations of daily living and reset goals and consider the impact of their MS less marked than they thought formerly [35]. More studies are needed to assess impact of rehabilitation on QoL and to understand the response shift phenomenon in the MS population.

Further, in addition to randomized controlled trial (RCT) methodology, a clinical practice improvement approach has also been applied to an inpatient MS cohort to understand the complex interplay of patient and process factors and impact on functional outcomes in rehabilitation for pwMS. In a pilot project (n = 24) [36], more than half of pwMS had moderate to severe fatigue, deficits in motor function and mood causing significant functional limitation, and two thirds required specialized nursing (e.g., continence care). Complexity of intervention was measured using the Northwick Park therapy dependency assessment (NPTDA) [37], which showed moderate dependency in physical, cognitive, and psychosocial domains. The NPTDA scores for these pwMS correlated strongly with FIM motor scores (Spearman rho −0.80) and Barthel index (rho −0.83) [36]. Further prospective studies are planned using appropriate tools to understand the “black box” of rehabilitation and the complex inter relationships of factors which impact function in this population.

Khan et al. [38] examined outcomes following inpatient rehabilitation episodes (n = 1010) for pwMS using the Australian Rehabilitation Outcomes Centre Database. The majority of patients were female and following rehabilitation discharged to the community. Improvement in function was assessed using the functional independence measure (FIM), with subclasses of pwMS based on motor FIM scores for severity in functional limitation. Authors reported significant functional improvement (P = 0.001) with rehabilitation in most MS groups, with year to year trend towards reducing hospital length of stay and FIM efficiency although these did not reach significance.

4. Neuropalliative Approach in PPMS

Since prognosis for PPMS is worse than other types of MS, the focus of rehabilitation is on managing disability and enhancing participation, and as disease progresses applying a “neuropalliative approach” [25]. The UK guidelines for managing long-term neurological conditions (LTNC) [39] are relevant to PPMS as they explore interaction between specialist neurology, rehabilitation, and palliative care services and how they work together to provide long-term support for people with LTNC and their carers. The key skills in neuropalliative care are shown in Table 4 [25]. Neurologists assess, diagnose, and manage disease, and the palliative care physicians’ manage distressing symptoms (nausea, vomiting, and breathlessness), support and counsel the person and family, end-of-life issues, and provide advance care planning. Rehabilitation physicians contribute to care by managing disability and provide adaptive aids (mobility and communication), procedures for spasticity management (botulinum toxin and phenol), and pain and behaviour management. As disease progresses goal posts change and rehabilitation and palliative approaches can overlap, that is, “neuropalliation”. Many issues in PPMS can be managed by closer collaboration and cross referral between the above specialties [40, 41]. The life circles diagram Figure 2 [25] shows the overlap between roles of neurology, palliative care, and rehabilitation physicians which are relevant to people with PPMS.


Every physician should have an understanding of the general principles of management and should also be aware of when and where to refer
if more specialist advice is needed in the areas shown below

Exposure to people with long-term neurological conditions(i) Understanding disease progression and prognosis

Symptom control(i) Ability to control key symptoms including:
  (1) pain in neurological conditions
  (2) breathlessness 
  (3) nausea/vomiting 
  (4) anxiety/depression 
  (5) spasticity management 
  (6) 24 hour postural support 
  (7) Bladder and bowels 
  (8) Seizure control

Communication(i) Basic understanding of common communication problems including dysphasia, dysarthria, cognitive speech disorders, and the different approaches to their management.
(ii) Ability to communicate with people who have cognitive/communication impairments 
  (1) using assistive communication devices
(iii) Communicating with patient and family 
  (1) breaking bad news 
  (2) addressing end of life decisions and advance care planning which will include choice over place of care.
  (3) Managing expectations.

Legal issues(i) Ability to assess for mental capacity and to assist people to make advance decisions and statements.
(ii) Understanding of the Mental Capacity Act 2005 and ability to work alongside lasting power of attorney/court appointed deputy or independent mental capacity advocates.

Additional skills for physicians specializing in neurological palliative care and rehabilitation

Specialist interventions(i) Local and intrathecal interventions for spasticity (e.g., injection of botulinum toxin/phenol and use of baclofen pumps).
(ii) Specialist procedures for pain control.
(iii) Management of confusion/unwanted behaviours–management under sections of the Mental Health Act 1983
(iv) Ventilation

Specialist equipment (i) Wheelchair seating systems
(ii) Environmental control systems
(iii) Specialist communication aids

Counselling and psychological support(i) Dealing with loss and fear of loss
(ii) Spiritual support
(iii) Bereavement–past and future

Welfare advice(i) Understanding the social care system and benefits
(ii) Vocational support

Additional sources of help and support(i) Understanding the interaction between health, social services and voluntary support agencies
(ii) Negotiating skills in obtaining services

(Printed with permission: RCP 2008 [25].)

5. Symptomatic Management and Rehabilitation

This section outlines the symptomatic and disability management of persons with MS, including PPMS. As PPMS is a progressive disease, regular patient evaluation and reassessment of treatment and management is required. The rehabilitation intervention principles and “neuropalliation” apply to this patient population. The management strategy includes education, therapy input, and medications.

PPMS presents primarily as progressive disease at onset; however, a minority may present with an acute relapse with a wide range of symptoms and signs. The most common patient reported symptoms that have a disabling impact are fatigue, mobility-related issues, and bladder and bowel dysfunction. One study of 101 pwMS showed the “linkage” of patient reported MS related problems and degree of limitation caused using the WHO ICF categories for the components: Body structure, Body Function, Activities and Participation, and Environmental factors [19], Table 5.


ICF codeChapter titleICF code descriptionTotal number of participants linked responses. n, %Number of participant and stage of disease
RRSPPPrr-SP

Body function

b130Global mental functionsEnergy and drive functions98, 97.035126147
b134Sleep84, 83.174721115
b140Specific mental functionsAttention66, 65.35371793
b144Memory62, 61.39371645
b152Emotional functions97, 96.045026147
b210Seeing and related functionsSeeing47, 46.53241643
b235Hearing vestibularVestibular (incl. balance functions)71, 70.303419135
b265Sensory functionsTouch34, 33.66151072
b280PainSensation of pain76, 75.253919126
B455CVS and respiratory functionsExercise tolerance functions*97, 96.045027137
b525Digestive systemDefecation89, 88.124921145
b620Urinary functionsUrination functions94, 93.075024137
b640Genital and reproductiveSexual functions57, 56.44321573
b730Muscle functionsMuscle power96, 95.055027136
b735Muscle tone94, 93.075026135
b740Muscle endurance function*93, 92.084925127
b760Movement functionsControl of voluntary movement functions*66, 65.35371883
b770Gait pattern functions*99, 98.025127138

Body Structure

s110Nervous systemBrain100, 99.015028148
s610Genitourinary systemUrinary system93, 92.084925127
s730Structures related to movementUpper extremity (arm, hand)44, 43.56251072
s750Lower extremity (leg, foot)97, 96.044927147
s760Trunk85, 84.164423126

Activities and participation

d160Applying knowledgeFocussing attention70, 69.31391696
d175Solving problems34, 33.6622822
d177Making decisions59, 58.42351653
d220General tasks and demandsUndertaking multiple tasks88, 87.134724125
d230Carrying out daily routine80, 79.214817105
d240Handling stress and other psychological demands101, 100.005128148
d430MobilityLifting and carrying objects53, 52.48301283
d440Fine hand use (picking up, grasping)51, 50.50261393
d445Hand and arm use37, 36.6321943
d450Walking101, 100.005128148
d455Moving around*99, 98.025127147
d465Moving around and using equipment (wheelchair, skates, etc.)98, 97.035027147
d470Using transportation (car, bus, train, plane, etc.)100, 99.015127148
d475Driving (riding bicycle and motorbike, driving car etc.)99, 98.025127147
d510Self careWashing oneself (bathing, drying, washing hands, etc.)41, 40.5926942
d520Caring for body parts (brushing teeth, shaving, grooming, etc.)40, 39.6024853
d570Looking after one’s health88, 87.134723144
d620Domestic lifeAcquisition of goods and services (shopping, etc.)92, 91.095024126
d630Preparation of meals (cooking etc.)89, 88.124824125
d640Doing housework (cleaning washing, laundry, and ironing)94, 93.075123146
d650Caring for household objects*84, 83.174622124
d660Assisting others87, 86.144822134
d750Interpersonal relationshipsInformal social relationships35, 34.65191222
d760Family relationships73, 72.284216114
d770Intimate relationships61, 60.40351574
d845WorkAcquiring keeping and terminating a job*73, 72.283919114
d850Remunerative employment90, 89.114524138
d870Economic lifeEconomic self-sufficiency84, 83.174422135
d910Community lifeCommunity Life79, 78.224021135
d920Recreation and leisure97, 96.045026147

Environmental Factors

e110Products and technologyFor personal consumption (food, medicines)101, 100.005128148
e120For personal indoor and outdoor mobility and transportation91, 90.104725127
e150Design, construction and building products and technology of buildings for public use70, 69.31391894
e210Natural environmentPhysical geography*39, 38.61211152
e225Climate99, 98.025028147
e310Support and relationshipsImmediate family45, 44.5527972
e315Extended family*42, 41.5826934
e460AttitudesSocietal attitudes31, 30.6913954
e540Services, systems, and policiesTransportation services, systems and policies68, 67.33381785
e580Health services, systems and policies79, 78.224518115

(Adapted from Khan and Pallant [19].)
5.1. Disabilities in MS
5.1.1. Fatigue

Fatigue is one of the most common symptoms in MS reported by up to 95% of pwMS. It is defined as “subjective” lack of physical or mental energy that is perceived by the individual or caregiver to interfere with usual activities and is present 60% of the time. In a sample of 656 patients with MS, 22% reported limitation in level of physical activity, 14% stated it required them to have more frequent rest breaks and 10% had to discontinue work due to fatigue [50]. Fatigue impacts on ability to work, social life and on activities of daily living. It is however difficult to predict and is unrelated to age, gender, disability as measured by Kurtzke Expanded Disability Status Scale (EDSS) [51] score or Neuro imaging status. Factors believed to contribute to fatigue in MS are summarized in Box 5.

There are a number of measures of MS-related fatigue [48] (see Table 6).


Name of scaleAuthor, year [ref.]PopulationSpecified fatigue subscalesNo. of itemsScoring

Modified fatigue impact scaleParalysed Veterans of America 1998 [42]MSPhysical, cognitive and psychosocial21Likert scale
Rochester fatigue diarySchwid et al., 2002 [43]MSLassitude (reduced energy)12 (1 item, 12 times over 24 h)Visual analogue scale
Fatigue descriptive scaleIriarte et al., 1999 [44]MSSpontaneous mention of fatigue, antecedent conditions, frequency, and impact on life50–3
Fatigue impact scaleFisk et al., 1994 [45]MSPhysical, cognitive, and psychosocial210–4
Fatigue assessment instrumentSchwartz et al., 1993 [46]Lynne, Chronic fatigue syndrome, lupus, Ms, dysthymia, healthyFatigue severity, situation specificity, consequences of fatigue, and responds to rest/sleep291–7
Single item visual analogue scale of fatigueKrupp et al., 1989 [47]MS, lupus, healthyNone1Visual analogue scale
Fatigue severity scaleKrupp et al., 1989 [47]MS, lupus, healthyNone9Likert scale

(Adapted from: MacAllister and Krupp [48].)

Treatment of fatigue should be individualized based on the medical and functional status of each patient. The quality and quantity of fatigue, and its impact on function is obtained on history. Other non-MS causes should be excluded (anaemia and hypothyroidism) and contributing factors identified. Medications and side effects should be reviewed. Nonpharmacologic approaches include education for patient and family (avoid heat, use airconditioners, and cooling gel vests), address lifestyle factors, for example, diet and exercise, avoid physical activity at mid afternoon (as a small rise in core body temperature worsens fatigue and MS lassitude or lack of energy). Fatigue management and pacing (regular rest breaks between activities, i.e., pacing activities throughout the day), energy conservation, and work simplification strategies to decrease energy consumption and increase economy of effort (use of assistive devices, adaptive equipment such as long handled aids/grab rails, gait aids such as a walking frame, and ankle foot orthoses to improve gait efficiency) and improve overall fitness by structured exercise programs for aerobic capacity and endurance.

There is limited evidence supporting drug efficacy in MS related fatigue. Modafinil, a “wake promoting” agent that selectively works in the hypothalamic pathways, has been reported to improve fatigue in progressive MS. Amino pyridines (potassium channel blockers) and amantadine (N-methyl D-aspartate receptor antagonist) have been used, however systematic reviews failed to find evidence for efficacy or safety of their use [52]. Depression may contribute to fatigue in some cases and there is empiric support for use of antidepressants in MS related fatigue. A clinical decision making flowchart for managing fatigue in MS is shown in Figure 3 [48].

5.1.2. Bladder, Bowel, and Sexual Dysfunction

Abnormalities in bladder function are primarily neurogenic and occur in over 80% of patients. Bladder dysfunction has a detrimental impact on mobility, everyday living activities, and on QoL in pwMS [53]. A recent RCT (n = 74) showed effectiveness of multidisciplinary rehabilitation for individualized bladder management program [54]. Approximately two thirds of patients on functional studies demonstrate overactive detrusor function, while the remainder exhibit underactivity. The external urethral sphincter complex may be synergic or dyssynergic with bladder contraction. Detrusor sphincter dyssynergia increases risk of pyelonephritis and renal failure due to combined effects of back pressure and reflux of infected urine into the kidney. Symptoms are unreliable in determining the precise underlying functional abnormality. Risk factors for progressive upper urinary tract dysfunction in MS, which require longer-term followup include: detrusor sphincter dyssynergia, age over 50 years, and male gender [55].

Urodynamic studies are mandatory to evaluate the pattern of neurogenic bladder dysfunction in an individual. On a day-to-day basis, general techniques for managing bladder care include scheduled fluid intake, timed voiding pattern, establishment of emptying techniques every three hours (tapping over suprapubic region, Credes maneuver), use of pads and undergarments, and use of bedside commode or urinal. Other simpler techniques such as voided volume charts will provide evidence of small frequent urine volumes suggesting detrusor hyperactivity. Postmicturition ultrasound should be performed regularly and if residual volumes exceed 100 mL, a regimen of intermittent clean self-catheterisation should be introduced. If this is not possible due to upper limb dysfunction or adductor spasm, long-term catheterisation should be considered.

Detrusor overactivity can be treated with anticholinergic medications (oxybutynin, imipramine, solifenacin, and tolterodine) and in severe cases with intravesical oxybutynin or botulinum toxin. Additional techniques for managing bladder include scheduled fluid intake, prompted voiding, avoidance of alcohol and caffeine, pelvic floor exercises and other behaviour modifications. For detrusor sphincter dysynergia regular attempts to void (light tapping), trial of antispasticity agents (baclofen), alpha adrenergic blocking agents (prazosin and clonidine), and anticholinergic medications (oxybutynin) with intermittent catheterization can be trialed. Detrusor underactivity causes incomplete bladder emptying and can be managed with intermittent catheterization; if these are unsuccessful, an indwelling catheter may be needed. Suprapubic catheterisation is preferable than urethral catheterization, as they have fewer complications including urinary infections, are easier to change, and permit normal sexual functioning. Figure 4 provides a flow chart for managing urinary incontinence in patients with long-term neurological conditions including PPMS [39].

Symptomatic lower urinary tract infections should be treated on the basis of a positive urine culture. Acidifying agents such as cranberry can reduce risk of recurrent urinary infections in neurogenic bladders. Symptomatic management of lower urinary tract symptoms includes the antidiuretic hormone desmopressin (DDAVP) nasal spray for nocturia and oral cannabinoids. Bladder retraining and pelvic floor exercises may be useful if patients are appropriately educated in conjunction with a physiotherapist. Patients should be provided with tips to prevent recurrent urinary infections such as awareness of signs of infection (cloudy urine or pain and odor), adequate fluid intake (8 glasses per day), increase urine acidity (vitamin C) or cranberry capsule daily, try to achieving complete bladder emptying, wiping front to back after going to the bathroom, and regular change of indwelling catheters (4–6 weekly).

Bowel dysfunction has been reported in 50% of pwMS, with constipation, and faecal incontinence. These result from autonomic dysfunction and abnormal rectal function. Absent rectal sensations increase risk of faecal incontinence, which can reflect decreased rectal filling sensation, poor sphincter and pelvic floor contraction and decreased rectal compliance. A recent study identified female sex, higher disability, and urinary dysfunction as independent predictors of developing anorectal dysfunction [56]. Bowel programs need to be effective (i.e., complete within 60 minutes from beginning of program to bowel evacuation). Patient education includes review of diet and bowel habits. The optimization of consistency of bowel contents is ensured by adequate oral intake, a diet high in fibre and laxatives (bowel softeners such as coloxyl) if necessary. Next is the facilitation of the movement of the bowel contents, a combination of osmotic (e.g., lactulose) and stimulants (e.g., senna) is effective and is the mainstay medical treatment. The iso-osmotic laxative polyethylene glycol (Movicol) has been shown to be effective in chronic constipation and is used in resistant cases. Frequent use of enemas should be avoided. The timing of a bowel program ideally should be postprandial when the gut is most active. Rectal stretching (suppository) can facilitate the defecation reflex and assist bowel evacuation. A flow chart outlining bowel management in pwMS is shown in Figure 5.

Sexual dysfunction in MS has been widely reported especially in patients with urinary symptoms [57]. Causes of sexual dysfunction may be primary (lack of lubrication, diminished genital sensations, erectile dysfunction), secondary (spasticity, pain, catheter care) or tertiary (marital difficulty, fear, and lack of confidence and self-worth). Men commonly report diminished libido, erectile and ejaculatory dysfunction. Women report diminished genital sensation, lubrication, and difficulty achieving orgasm. Rehabilitation includes education about intimacy and sexuality, management of fatigue, positioning, and mechanics, information about aids (tumescence devices), specific suggestions and techniques, and referral for sexual counselling. The use of oral phosphodiesterase inhibitors (e.g., sildenafil) have been successful in treating erectile dysfunction in men; their role in women has not been established. In addition to intracorporeal pharmacotherapy, papaverine has now been replaced by prostaglandin E1 by intracavernosal injection or urethral application.

5.1.3. Mobility Related Symptoms

Mobility can be affected in MS from a combination of motor (weakness and spasticity), sensory (proprioception loss, ataxia), fatigue, and visual impairments.

Spasticity
Spasticity, a velocity-dependent increase in muscle tone, is a common complication of MS. Muscle shortening and restricted movements lead to decreased tissue compliance and biomechanical difficulties (contractures) which can limit a person’s activity (mobility, ability to transfer, perform self-care tasks, and pain) and participation (unable to drive or work). Management of spasticity in pwMS is complicated due to lesions in the brain and spinal cord, numerous other secondary MS-related impairments, and their associated polypharmacy. There are limited studies which do not suggest improved outcomes of one strategy for managing spasticity compared with another. Two useful measure of spasticity include the spasm frequency scale [58] and the modified ashworth scale [59]. The spasm frequency scale is obtained from history, and is a 0–4 non interval scale: 0: no spasms, 4: 10 spontaneous spasms per hour. The modified ashworth scale is obtained after clinical examination and is also a non interval scale of 0–4 (although it includes a value for 1+), with 0: “no increase in tone”, 4: “affected part is rigid”. More recently, a systematic review found the Tardieu scale to be a more sensitive measure for spasticity; however, further validity validation of this scale for various muscle groups is required [60].
The treatment goals change with progression of disease. Early in the course of the disease, spasticity can interfere with functional activities and also cause gait inefficiency, which in turn increases fatigue. On the other hand, as muscles weaken, some patients rely on their spasticity to keep them on their feet. Carefully targeted intervention for those elements of spasticity that are unwanted can assist with energy conservation and so keep pwMS mobile and independent for longer. Later on, the focus of treatment is more on improving ease of maintaining hygiene, prevention of contractures and pain reduction. Management involves patient education, therapy intervention, and medication [28]. The aims of therapy are awareness of symptoms related to spasticity and awareness of factors that can worsen spasticity for example, noxious stimuli, sudden movements, anxiety; correct positioning and alignment, and a stretching program. The mainstay of treatment is maintaining muscle length, so the importance of positioning and physical management (such as a regular standing regimen) cannot be over-estimated. Drugs are an adjunct to these interventions and may be given orally or by intramuscular, intraneural, or intrathecal injection.
Oral antispasticity agents are first-line therapy for generalised spasticity [28]. The most commonly prescribed oral agents include baclofen, tizanidine, clonazepam, and dantrolene. Baclofen (gamma amino butyric acid agonist) remains the agent of first choice though its use is restricted by side effects including weakness, fatigue, and cognitive impairment. Tizanidine (central acting α2 adrenergic agonist) can be used in conjunction with baclofen or in isolation in patients who cannot tolerate or have no response to baclofen. Clonazepam (benzodiazepine) is particularly effective at treating nocturnal spasms. Its side effect profile includes sedation and effects on cognition. Dantrolene acts at the level of the muscle and can be used with any of the above agents for severe generalized spasticity. Its use is limited by its side-effect profile and poor tolerability. 4-Aminopyridine (Dalfampridine and Fampridine) (voltage-gated potassium channel blocker) has been shown to provide improvement in lower limb function, but toxicity with seizures and encephalopathy can occur at therapeutic doses [61, 62]. Other pharmacological agents such as Memantine did not show any benefit in treatment of spasticity [63]. Cannabis extracts are reported to have positive effect on spasticity and can be prescribed orally or via nasal spray [28]. Cannabinoids act on CB1 receptors in the CNS to inhibit cyclic AMP and voltage-dependent calcium channels, causing antispastic effect.
Intrathecal Baclofen (ITB) is effective for severe generalised spasticity, particularly in the lower limbs. It requires lower doses and has improved tolerability due to less sedative and cognitive side effects. However, ITB withdrawal syndrome (incorrect dosage and pump failure) can be life threatening, and therefore, this treatment should only be managed in specialist units [64]. For focal spasticity, botulinum toxin injected into the affected muscle(s) can be effective [65]. Other localized spasticity (adductor muscles) can be treated with phenol neurolysis. Surgical options (tendon release surgery) are reserved for severe spasticity, causing pain, interfering with care, and/or limiting activities of daily living.

Ataxia
Cerebellar problems such as tremor, ataxia, and incoordination are common in pwMS. The action (postural- intention) tremor reflects brainstem-cerebellar circuitary lesions and can be disabling and is often difficult to treat. Symptomatic treatment for tremor includes identification of type of tremor, trigger factors and part of body involved. Use of assistive devices (braces and support) and evaluation for therapy may be helpful. Limited benefit from drug therapy using Ondansetron (for cerebellar tremor), propanolol, and combined therapy with lamotrigine and gabapentin have been reported. Surgical ablative and stimulation techniques (ventral intermediate thalamic nucleus) are currently being trialed.
Truncal ataxia can occur in up to 70% of pwMS, often accompanied by tremor. It has a significant effect on motor coordination (similar to weakness) and interferes with balance and mobility, increasing predisposition to falls and injury. Patient education and safety in daily living tasks is emphasized as rehabilitation strategies, which include improvement in posture and alignment, proximal stabilization (pectoral and pelvic girdle musculature), coordination exercises, and assistive devices such as the use of distal weights around the wrists to dampen tremor and the use of walking frames or elbow crutches enhance gait stability. Falls prevention strategies and environmental modification (installation of grab rails, nonskid floor mats) can be helpful. In one small RCT (n = 23) [66], pwMS were randomized to specific physiotherapy strategies such as (a) facilitation therapy (individualized, passive and active manual assistance, postural control, and component practice as in Bobath technique) and (b) task oriented therapy (nonindividualized, hands off acceptance of compensatory strategies and functional tasks such as stair climbing and treadmill walking). Although patients in both groups showed improvement in gait scores, balance tests and global mobility indices, those in the facilitation group had nonsignificant trends towards greater benefit in all categories. Medications for ataxia are similar to those used for treating tremors (isoniazid, clonazepam, propanolol, gabapentin, and Ondansetron). A recent systematic review found no evidence that medication or neurorehabilitation strategies provide sustained improvement in ataxia in pwMS [67]. Surgical interventions such as thalamotomy or thalamic stimulation in MS have produced limited success.

5.1.4. Pain and Paroxysmal Symptoms

Pain can be acute or chronic. The underlying mechanisms of pain in MS are unclear and have been linked with the differentiation and disinhibition of central and pain pathways [68, 69] with CNS lesions causing hyperexcitability and with increased neuronal activity at the site of the lesion in the spinal cord [70]. Acute pain may be associated with active inflammatory process. Chronic pain may be due to the MS process itself or from complications that arise from it such as trigeminal neuralgia, spasms/spasticity, and musculoskeletal posture and gait-related problems [71].

In one recent Australian series (n = 94) 60% of patients reported chronic pain, of these 61% had dysesthetic pain and 70% had episodic increases in pain [72]. Chronic pain in MS impacts on activities of daily living [71] and interferes with ability to work [73]. A recently published study (n = 62) performed cluster analysis to classify patients into three cognitive behavioral groups (adaptive copers, dysfunctional and interpersonally distressed) and suggested possible cut points to aid clinicians in classifying patients into clusters for individualized treatment [74]. The severity of depression is reported to be higher in persons with MS with chronic pain than those without pain. There is also increased interference with daily activities, more severe symptoms of depression and negative effect on relationships with partners and family [71]. Treatment of chronic pain has been discussed elsewhere [75]. A multidisciplinary team approach may be needed and referral to pain clinic may be helpful.

A systematic approach initially using monotherapy to maximum doses before polytherapy is imperative Amitriptyline is effective for chronic dysesthetic pain. Carbamazepine is the drug of choice for trigeminal neuralgia if not tolerated then alternatives include gabapentin, lamotrigine, and phenytoin [76]. Transcutaneous electrical nerve stimulation to lower back of pwMS appears promising [77]. Surgical options are percutaneous procedures and rarely microvascular surgery [78]. Carbamazepine and gabapentin are agents of choice for other paroxysmal symptoms (tonic spasms, ataxia, or sensory symptoms like Lhermitte’s). Cannabis-based preparations are effective for pain in pwMS [79] but are reserved for cases where standard therapies have failed or are not tolerated. There is no evidence to support routine use of intrathecal morphine for pain management in the MS population. Pregabalin, an isomer of GABA with selectively binds to the alfa2-delta protein of the voltage-gated calcium channels, has been shown to be efficacious in the management of peripheral neuropathic pain of various causes including MS [80, 81].

5.1.5. Cognitive Deficits

Current estimates of prevalence of neuropsychological problems in MS are approximately 50% [82, 83]. The neurocognitive and behavioural deficits in MS, and suggested treatments are discussed in a recent review [84]. Cognitive problems result from affected pathways in the cerebral white matter (limbic system, the midbrain, and brainstem), which transmit to, and communicate with, higher-level cortical regions throughout the brain. These deficits can be a major impediment to rehabilitation and include: inability to store and to retrieve information, decreased memory, attention and speed of processing, and limitations in emotion, personality, and behaviour [8486].

Many guidelines exist for neuropsychological research in MS [84]. Neuropsychological interventions are designed to enhance a person’s ability to function in all areas of family and community life, which are meaningful for pwMS. A neuropsychological assessment can be helpful to delineate problems and suggest compensatory techniques. These include functionally oriented therapies based on specific deficits: compensatory strategies (using intact skills or external aids to improve function), substitution (learnt use of intact cognitive abilities to circumvent a problem), or scheduling (templates and structured programs) may assist with everyday living tasks.

A systematic review reported that cognitive behaviour therapies (CBT) were beneficial for pwMS in terms of coping with, and adjustment to MS [33]. Other specific cognitive rehabilitation protocols are being evaluated [87]. Although the evidence for individual interventions is limited, computer-based retraining program was shown to improve deficits related to attention [88]. Medications such as amantadine, glatiramer acetate, memantine, and donepezil failed to improve cognitive function in MS [8992]; others such as methylphenidate have not yet been studied in pwMS.

5.1.6. Visual and Brainstem Symptoms

Visual disturbances were reported by 58% of pwMS in one large cohort [93]. Referral to “low vision clinic” may be required for decreased visual acuity (optic neuritis). The visual dysfunction may also result from involuntary eye movement disorders (nystagmus and opsoclonus) [28]. Patient education, use of adaptive visual aids (prisms and magnifying lens), and occasionally medications such as baclofen, isoniazid, and gabapentin may be helpful for involuntary eye movements [94]. Referral to occupational therapy and low vision clinics can be helpful for neuromobility services such as practicing outdoor mobility to improve safe community access.

Vestibular involvement in MS is frequent and causes vertigo and often associated with other signs of brainstem dysfunction. Specific vestibular physiotherapy exercises (such as Cawthorne-Cooksey protocol) may be helpful. Effective speech therapy for dysarthria for MS includes control of speech rate, voice emphasis and power, and reduction in phrase length [9597]. Dysphagia occurs in about 34%–43% of pwMS [98, 99]. Fatigue, tremors, weakness, and incoordination exacerbate dysphagia and dysarthria. Spasticity is worsened by malnutrition. For the most severely affected pwMS, maintenance of nutritional balance may require placement of a percutaneous peg for feeding. This requires specialized nutritional and speech pathology services. Videofluoroscopy and clinical assessment is recommended for more disabled persons [100]. Speech therapy can provide compensatory strategies to avoid aspiration, correct posture (sitting up when eating), alter food consistency, and provide education to prevent complications (pneumonia) [99].

5.1.7. Psychiatric and Psychological Dysfunction

The prevalence of major depressive disorder in pwMS is reportedly between 27%–54%, and nearly double the prevalence in persons without MS over 12 months (15.7% versus 7.4%) [101]. There was also an age effect, with a prevalence of 25% in adults between 18 and 45 years. The relationship between depression and cognitive dysfunction, and treatment are discussed elsewhere [71]. Depression impacts’ on all aspects of life and can amplify symptoms, leading to further limitation in function, and interferes with disease management [102]. Major depressive disorder is linked to objective cognitive difficulties (attention and memory) [103].

Selective serotonin reuptake inhibitors are widely used to treat depression in rehabilitation. One study (n = 630) compared CBT, the antidepressant Sertraline, and group psychotherapy [104]. CBT and Sertraline were more efficacious than group therapy, and improvement in depressive symptoms persisted at 6-month followup. Symptoms of depression also improved in persons who received an alternate approach—an eight-week telephone cognitive behavioural intervention compared to usual care [105]. This approach was adapted to address barriers such as transportation and access pwMS. Exercise improves mood, fatigue and QoL [105, 106] and is as effective as standard antidepressant medication and psychotherapy [107].

Other approaches to treat depression include behaviour activation (which treats depression by increasing access to positive reinforcement and decreasing frequency and intensity of aversive events and consequences) [108] and interpersonal therapy—an evidence based approach that focus’ on role disputes and role transitions as a framework for therapy [109].

Psychosocial issues include inability to cope (patient and family), stress, financial considerations, and marital discord. A recent Australian study outlined factors impacting on MS caregivers in a community setting [110]. More strain was reported in caregivers caring for pwMS with depression, anxiety, and stress levels, with a poorer QoL for both the carer and care recipient. Education and support, stress management, and coping skills can positively influence health and wellbeing and may require clinical psychology and psychiatry. Neuropsychological counselling improved insight and social skills training compared with standard counselling, in reducing disinhibition and socially aggressive behaviour especially in cognitively impaired pwMS [111].

5.1.8. General Reconditioning and Ambulation

Reduced physical activity and exercise due to MS limitations have been discussed elsewhere [112]. Causal factors include decreased muscle strength, aerobic capacity, maximal vital capacity, and increase in neuromuscular tension, fatigue, anxiety, and depression. Exercise programs do not alter the MS disease course but do prevent secondary effects of inactivity and improve fatigue and sense of well-being. An integrated exercise program incorporates: a daily passive range of motion, an active range of motion with gravity eliminated or against gravity as allowed by strength, and specific muscle training (three sets of 10 repetitions) is recommended for focal weakness, when fatigue and heat sensitivity are issues [112, 113]. Active exercise for 20–30 minutes 3 times per week, with a 5 minute warmup and cool-down, stretching for lower limbs and back is effective [112], while aerobic exercises for cardiovascular fitness are important for overweight persons [114].

Gait is impaired by weakness, spasticity, incoordination, balance, fatigue, and visual disturbances. For ambulation, a graded program should improve trunk control and balance, followed by normalizing tone, flexibility, and range of motion and then strength. Graded sitting and standing tolerance program and tilt table routine prior to gait training may be required. Proprioceptive, tactile, and visual cues are also helpful. Specific ambulation aids (elbow crutches, walking frames, and ankle foot orthoses) and mobility devices (wheel chairs and scooters) can decrease energy expenditure and improve safety and endurance [115]. A person’s strength, motor control, cognition, and emotional response are all considered prior to prescription. Wheelchairs are customized for each person, such as appropriate seating, posture support, tilt in space mechanism, and manipulation of components (arm rests, foot plates). Scooters assist those with ataxia and fatigue. Weighted wrist cuffs and walkers may help dampen tremors [116].

5.1.9. Activities of Daily Living

Improvement in functional independence and maintenance is a key rehabilitation goal. Principles of occupational therapy (OT) in MS have been previously discussed [117]. OT was effective in improving function in pwMS, using retraining techniques for personal, domestic, and community tasks, mainly in inpatient settings [34]. However, in a recent systematic review [31] patient education and energy conservation strategies in MS were found to be inconclusive due to methodological weakness of included studies. OT should concentrate on activities that pwMS would use in practice, rather than on activities that people may not value because of environmental or behavioural circumstances [85].

5.1.10. Driving

Although a recent study did not find excessive risk for fatal road accidents in pwMS [118], many issues impact on driving, especially cognitive and perceptual considerations [119]. Driving assessments may be required based on each individual’s deficits. In persons with PPMS, if there are concerns, then a driving assessment by the occupational therapist is recommended. Fatigue-related issues due to MS may impact on the ability of the pwMS to drive for 45 minutes without a break—this has implications for holding a full driving license (Australia). Restrictions such as driving during day time only (poor night vision) or driving in localized area may be required. For more severely affected individuals, other specialized driving adaptations such as hand brakes, use of spinner knob on driving wheel, extra rear view mirrors, and motorized pulleys for folding and storage of wheelchairs may be needed.

5.1.11. Employment

An estimated 65% of pwMS were working at the time of their diagnosis, and between 25% and 35% of these persons remain in work force 5–10 years of diagnosis [120]. Fatigue, urinary urgency and incontinence, and visual and mobility issues are the main barriers for continued employment. Many pwMS leave workforce prematurely, or on advice of a well-meaning health care provider or family member. Rehabilitation input may assist in continued employment. Reasonable accommodations for MS include flexible working hours, work at home options, transportation, accessible work environment (bathroom, desk), memory aids (planners and diaries), vision aids (voice recognition software), and air-conditioning. Return-to-work programs are customized, graded (gradual increase in working hours), or altered to suit the individual with MS [121]. These programs are coordinated by the Vocational Rehabilitation Services, in collaboration with the employee, employer and the treating rehabilitation team. Vocational rehabilitation interventions for pwMS focus on job retention strategies rather than retraining for new jobs. There are a very limited number of high-quality studies at present that address the efficacy of vocational rehabilitation in the MS population. A recent review, therefore, found insufficient evidence as yet to support vocational rehabilitation in pwMS [122].

6. Summary

The multiple concurrent MS-related physical, cognitive, emotional, and social issues make rehabilitation challenging in persons with PPMS. Rehabilitation measures do not alter the course of MS disease. The overriding principle in setting goals for a pwMS is to maximize functional independence and safety, minimize complications and problems that result from decreased mobility, compensate for loss of function, and improve quality of life. With disease progression a “neuropalliative” approach is required. Rehabilitation should be viewed as an ongoing process to anticipate problems and to maintain and restore maximum function and QoL for persons with PPMS.

Conflict of Interests

The authors report no conflict of interests.

References

  1. Programme for Neurological Diseases and Neurosciences Department of Mental Health and Substance Abuse, Atlas: Country Resources for Neurological Disorders: Results of a Collaborative Study of World Health Organization and World Federation of Neurology, World Health Organization, Geneva, Switzerland, 2004.
  2. N. G. Torkildsen, S. A. Lie, J. H. Aarseth, and K. M. Myhr, “Survival and cause of death in multiple sclerosis: results from a 50-year follow-up in Western Norway,” Multiple Sclerosis, vol. 14, no. 9, pp. 1191–1198, 2008. View at: Publisher Site | Google Scholar
  3. F. Khan, T. McPhail, C. Brand, L. Turner-Stokes, and T. Kilpatrick, “Disability profile and quality of life in multiple sclerosis in an Australian community cohort,” International Journal of Rehabilitation Research, vol. 29, no. 2, pp. 87–96, 2006. View at: Publisher Site | Google Scholar
  4. R. Rovaris, E. Judica, J. Sastre-Garriga et al., “Large-scale, multicentre, quantitative MRI study of brain and cord damage in primary progressive multiple sclerosis,” Multiple Sclerosis, vol. 14, no. 4, pp. 455–466, 2008. View at: Publisher Site | Google Scholar
  5. X. Montalban, “Primary progressive multiple sclerosis,” Current Opinion in Neurology, vol. 18, no. 3, pp. 261–266, 2005. View at: Google Scholar
  6. D. Bar-Zohar, A. Agosta, D. Goldstaub, and M. Filippi, “Magnetic resonance imaging metrics and their correlation with clinical outcomes in multiple sclerosis: a review of the literature and future perspectives,” Multiple Sclerosis, vol. 14, no. 6, pp. 719–727, 2008. View at: Publisher Site | Google Scholar
  7. L. Ramió-Torrentà, J. Sastre-Garriga, G. T. Ingle et al., “Abnormalities in normal appearing tissues in early primary progressive multiple sclerosis and their relation to disability: a tissue specific magnetisation transfer study,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 77, no. 1, pp. 40–45, 2006. View at: Publisher Site | Google Scholar
  8. A. Kutzelnigg, C. F. Lucchinetti, C. Stadelmann et al., “Cortical demyelination and diffuse white matter injury in multiple sclerosis,” Brain, vol. 128, no. 11, pp. 2705–2712, 2005. View at: Publisher Site | Google Scholar
  9. M. Rovaris, M. Bozzali, G. Santuccio et al., “In vivo assessment of the brain and cervical cord pathology of patients with primary progressive multiple sclerosis,” Brain, vol. 124, no. 12, pp. 2540–2549, 2001. View at: Google Scholar
  10. M. Bieniek, D. R. Altmann, G. R. Davies et al., “Cord atrophy separates early primary progressive and relapsing remitting multiple sclerosis,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 77, no. 9, pp. 1036–1039, 2006. View at: Publisher Site | Google Scholar
  11. C. H. Polman, S. C. Reingold, G. Edan et al., “Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald criteria”,” Annals of Neurology, vol. 58, no. 6, pp. 840–846, 2005. View at: Publisher Site | Google Scholar
  12. C. H. Polman, S. C. Reingold, B. Banwell et al., “Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria,” Annals of Neurology, vol. 69, no. 2, pp. 292–302, 2011. View at: Publisher Site | Google Scholar
  13. N. Grytten, S. A. Torkildsen, J. H. Aarseth, H. Nyland, and K. M. Myhr, “Survival and cause of death in multiple sclerosis: results from a 50-year follow-up in Western Norway,” Multiple Sclerosis, vol. 14, no. 9, pp. 1191–1198, 2008. View at: Publisher Site | Google Scholar
  14. D. A. Cottrell, M. Kremen-chutzky, G. P. A. Rice et al., “The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis,” Brain, vol. 122, no. 4, pp. 625–639, 1999. View at: Publisher Site | Google Scholar
  15. World Health Organization (WHO), The International Classification of Functioning, Disability and Health (ICF), World Health Organization, Geneva, Switzerland, 2001.
  16. S. A. Steins, B. O’Brien, and M. Young, “The person, disablement and the process of rehabilitation,” in PM& R Secrets, B. O’Young, M. Young, and S. A. Steins, Eds., pp. 1–8, Hanley & Belfus, Philadelphia, Pa, USA, 1997. View at: Google Scholar
  17. J. S. Wolinsky, P. A. Narayana, P. O'Connor et al., “Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial,” Annals of Neurology, vol. 61, no. 1, pp. 14–24, 2007. View at: Publisher Site | Google Scholar
  18. F. Khan and J. F. Pallant, “Use of the International Classification of Functioning, Disability and Health (ICF) to identify preliminary comprehensive and brief core sets for multiple sclerosis,” Disability and Rehabilitation, vol. 29, no. 3, pp. 205–213, 2007. View at: Publisher Site | Google Scholar
  19. F. Khan and J. F. Pallant, “Use of International Classification of Functioning, Disability and Health (ICF) to describe patient-reported disability in multiple sclerosis and identification of relevant environmental factors,” Journal of Rehabilitation Medicine, vol. 39, no. 1, pp. 63–70, 2007. View at: Publisher Site | Google Scholar
  20. G. H. Kraft and J. Y. Cui, “Multiple sclerosis,” in Physical Medicine and Rehabilitation: Principles and Practice, J. A. Delisa, Ed., pp. 1753–1769, 4th edition, 2005. View at: Google Scholar
  21. D. T. Wade, Measurement in Neurological Rehabilitation, Oxford University Press, 1992.
  22. J. C. Hobart, D. L. Lamping, J. A. Freeman et al., “Evidence based measurement: which disability scale for neurologic rehabilitation?” Neurology, vol. 57, no. 4, pp. 639–644, 2001. View at: Google Scholar
  23. D. A. Rossiter, A. Edmondson, R. Al-Shahi et al., “Integrated pathways in multiple sclerosis: completing the audit cycle,” Multiple Sclerosis, vol. 4, no. 2, pp. 85–89, 1998. View at: Google Scholar
  24. F. Khan, J. F. Pallant, and L. Turner-Stokes, “Use of goal attainment scaling in inpatient rehabilitation for persons with multiple sclerosis,” Archives of Physical Medicine and Rehabilitation, vol. 89, no. 4, pp. 652–659, 2008. View at: Publisher Site | Google Scholar
  25. Royal College of Physicians, National Council for Palliative care. British Society of Rehabilitation Medicine, Concise Guidance to Good Practice Series, vol. 10, Royal College of Physicians, London, UK, 2008.
  26. National Institute for Clinical Excellence [NICE], “Multiple Sclerosis: Management of multiple sclerosis in primary and secondary care. Clinical Guidelines -8,” NICE, ISBN: 1842574426, 2003, http://www.nice.org.uk. View at: Google Scholar
  27. Department of Health, “The National Service Framework [NSF] for Long -term Conditions,” DoH, UK, 2005. View at: Google Scholar
  28. A. J. Thompson, “Symptomatic management and rehabilitation in multiple sclerosis,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 71, no. 2, pp. 22–27, 2001. View at: Google Scholar
  29. F. Khan, L. Turner-Stokes, L. Ng, and T. Kilpatrick, “Multidisciplinary rehabilitation for adults with multiple sclerosis,” The Cochrane Database of Systematic Reviews, no. 2, Article ID CD006036, 2007. View at: Google Scholar
  30. M. B. Reitberg, D. Brooks, B. M. J. Utidehaag, and G. Kwakkel, “Exercise therapy for multiple sclerosis,” Cochrane Database of Systematic Review, no. 3, Article ID CD003980, 2004. View at: Google Scholar
  31. E. M. Steultjens, J. Dekker, L. M. Bouter, M. Cardol, J. C. van de Nes, and C. H. van den Ende, “Occupational therapy for multiple sclerosis,” The Cochrane Database of Systematic Reviews, no. 3, p. CD003608, 2003. View at: Google Scholar
  32. N. A. Baker and L. Tickle-Degnen, “The effectiveness of physical, psychological, and functional interventions in treating clients with multiple sclerosis: a meta-analysis,” American Journal of Occupational Therapy, vol. 55, no. 3, pp. 324–331, 2001. View at: Google Scholar
  33. P. W. Thomas, S. Thomas, C. Hillier, K. Galvin, and R. Baker, “Psychological interventions for multiple sclerosis,” The Cochrane Database of Systematic Reviews, no. 1, p. CD004431, 2006. View at: Google Scholar
  34. F. Khan, J. F. Pallant, C. Brand, and T. J. Kilpatrick, “Effectiveness of rehabilitation intervention in persons with multiple sclerosis: a randomised controlled trial,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 79, no. 11, pp. 1230–1235, 2008. View at: Publisher Site | Google Scholar
  35. L. Costelloe, K. O'Rourke, H. Kearney et al., “The patient knows best: significant change in the physical component of the Multiple Sclerosis Impact Scale (MSIS-29 physical),” Journal of Neurology, Neurosurgery and Psychiatry, vol. 78, no. 8, pp. 841–844, 2007. View at: Publisher Site | Google Scholar
  36. F. Khan, J. F. Pallant, N. Zhang, and L. Turner-Stokes, “Clinical practice improvement approach in multiple sclerosis: a pilot study,” International Journal of Rehabilitation Research, vol. 33, no. 3, pp. 238–247, 2010. View at: Publisher Site | Google Scholar
  37. L. Turner-Stokes and A. Shaw, “The Northwick Park Therapy Dependency Score (NPTDA): development, preliminary evaluation and application,” A report for the Department of Health Project Grant 030/0066, Kings College, London, UK, 2006. View at: Google Scholar
  38. F. Khan, L. Turner-Stokes, T. Stevermuer, and F. Simmonds, “Multiple sclerosis rehabilitation outcomes: lessons learnt from an Australian casemix dataset,” Multiple Sclerosis, vol. 15, no. 7, pp. 869–875, 2009. View at: Google Scholar
  39. Department of Health: long term conditions NSF Team, “The National Services Framework for Long Term Neurological Conditions,” Department of Health, UK, 2005. View at: Google Scholar
  40. D. C. Traue and J. R. Ross, “Palliative care in non-malignant diseases,” Journal of the Royal Society of Medicine, vol. 98, no. 11, pp. 503–506, 2005. View at: Publisher Site | Google Scholar
  41. L. Turner-Stokes, N. Sykes, E. Silber, A. Khatri, L. Sutton, and E. Young, “From diagnosis to death: exploring the interface between neurology, rehabilitation and palliative care in managing people with long-term neurological conditions,” Clinical Medicine, vol. 7, no. 2, pp. 129–136, 2007. View at: Google Scholar
  42. Paralysed Veterans of America, “Multiple Sclerosis Council for Clinical Practice Guidelines. Fatigue and Multiple Sclerosis. Evidence based management strategies for fatigue,” in Multiple Sclerosis, Paralysed Veterans of America, 1998. View at: Google Scholar
  43. S. R. Schwid, M. Covington, B. M. Segal, and A. D. Goodman, “Fatigue in multiple sclerosis: current understanding and future directions,” Journal of Rehabilitation Research and Development, vol. 39, no. 2, pp. 211–224, 2002. View at: Google Scholar
  44. J. Iriarte, G. Katsamakis, and P. de Castro, “The Fatigue Descriptive Scale (FDS): a useful tool to evaluate fatigue in multiple sclerosis,” Multiple Sclerosis, vol. 5, no. 1, pp. 10–16, 1999. View at: Publisher Site | Google Scholar
  45. J. D. Fisk, P. G. Ritvo, L. Ross, D. A. Haase, T. J. Marrie, and W. F. Schlech, “Measuring the functional impact of fatigue: initial validation of the fatigue impact scale,” Clinical Infectious Diseases, vol. 18, supplement 1, pp. S79–S83, 1994. View at: Google Scholar
  46. J. E. Schwartz, L. Jandorf, and L. B. Krupp, “The measurement of fatigue: a new instrument,” Journal of Psychosomatic Research, vol. 37, no. 7, pp. 753–762, 1993. View at: Publisher Site | Google Scholar
  47. L. B. Krupp, N. G. LaRocca, J. Muir-Nash, and A. D. Steinberg, “The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus,” Archives of Neurology, vol. 46, no. 10, pp. 1121–1123, 1989. View at: Google Scholar
  48. W. S. MacAllister and L. B. Krupp, “Multiple sclerosis related fatigue,” Physical Medicine and Rehabilitation Clinics of North America, vol. 16, no. 2, pp. 483–502, 2005. View at: Publisher Site | Google Scholar
  49. A. E. Miller, F. D. Lublin, and P. K. Coyle, Multiple Sclerosis in Clinical Practice, Martin Dunitz, Taylor and Francis, UK, 2003.
  50. J. E. Freal, G. H. Kraft, and J. K. Coryell, “Symptomatic fatigue in multiple sclerosis,” Archives of Physical Medicine and Rehabilitation, vol. 65, no. 3, pp. 135–138, 1984. View at: Google Scholar
  51. J. F. Kurtzke, “Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS),” Neurology, vol. 33, no. 11, pp. 1444–1452, 1983. View at: Google Scholar
  52. A. Solari, B. Uitedehaag, G. Guiliani et al., “Aminopridines for symptomatic treatment in multiple sclerosis,” The Cochrane Database of Systematic Reviews, no. 4, Article ID CD001330, 2002. View at: Google Scholar
  53. F. Khan, J. F. Pallant, T. L. Shea, and M. Whishaw, “Multiple sclerosis: prevalence and factors impacting bladder and bowel function in an Australian community cohort,” Disability and Rehabilitation, vol. 31, no. 19, pp. 1567–1576, 2009. View at: Publisher Site | Google Scholar
  54. F. Khan, J. F. Pallant, J. I. Pallant, C. Brand, and T. J. Kilpatrick, “A randomised controlled trial: outcomes of bladder rehabilitation in persons with multiple sclerosis,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 81, no. 9, pp. 1033–1038, 2010. View at: Publisher Site | Google Scholar
  55. M. de Sèze, A. Ruffion, P. Denys, P. A. Joseph, and B. Perrouin-Verbe, “The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines,” Multiple Sclerosis, vol. 13, no. 7, pp. 915–928, 2007. View at: Publisher Site | Google Scholar
  56. E. Munteis, M. Andreu, M. J. Téllez, D. Mon, A. Ois, and J. Roquer, “Anorectal dysfunction in multiple sclerosis,” Multiple Sclerosis, vol. 12, no. 2, pp. 215–218, 2006. View at: Publisher Site | Google Scholar
  57. F. Khan, J. F. Pallant, L. Ng, and M. Whishaw, “Sexual dysfunction in multiple sclerosis,” Sexuality and Disability, vol. 29, pp. 101–111, 2011. View at: Google Scholar
  58. R. D. Penn, S. M. Savoy, D. Corcos et al., “Intrathecal baclofen for severe spinal spasticity,” The New England Journal of Medicine, vol. 320, no. 23, pp. 1517–1521, 1989. View at: Google Scholar
  59. B. Ashworth, “Preliminary trial of carisoprodol in multiple sclerosis,” Practitioner, vol. 192, pp. 540–542, 1964. View at: Google Scholar
  60. A. Haugh, A. Pandyan, and G. Johnson, “A systematic review of the Tardieu scale for the measurement of spasticity,” Disability and Rehabilitation, vol. 28, no. 15, pp. 899–907, 2006. View at: Publisher Site | Google Scholar
  61. A. D. Goodman, T. R. Brown, K. R. Edwards et al., “A phase 3 trial of extended release oral dalfampridine in multiple sclerosis,” Annals of Neurology, vol. 68, no. 4, pp. 494–502, 2010. View at: Publisher Site | Google Scholar
  62. A. D. Goodman, T. R. Brown, L. B. Krupp et al., “Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial,” The Lancet, vol. 373, no. 9665, pp. 732–738, 2009. View at: Publisher Site | Google Scholar
  63. L. R. Mehata, M. P. McDermott, A. D. Goodman et al., “A randomised trial of mematine as treatment for spasticity in multiple sclerosis,” Multiple Sclerosis, vol. 16, no. 2, pp. 248–251, 2010. View at: Google Scholar
  64. I. Mohammed and A. Hussain, “Intrathecal baclofen withdrawal syndrome—a life-threatening complication of baclofen pump: a case report,” BMC Clinical Pharmacology, vol. 4, no. 6, 2005. View at: Publisher Site | Google Scholar
  65. N. Hyman, M. Barnes, B. Bhakta et al., “Botulinum toxin (Dysport®) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study,” Journal of Neurology Neurosurgery and Psychiatry, vol. 68, no. 6, pp. 707–712, 2000. View at: Publisher Site | Google Scholar
  66. S. E. Lord, D. T. Wade, and P. W. Halligan, “A comparison of two physiotherapy treatment approaches to improve walking in multiple sclerosis: a pilot randomized controlled study,” Clinical Rehabilitation, vol. 12, no. 6, pp. 77–86, 1998. View at: Google Scholar
  67. R. J. Mills, L. Yap, and C. A. Young, “Treatment for ataxia in multiple sclerosis,” The Cochrane Database of Systematic Reviews, no. 1, Article ID CD005029, 2007. View at: Google Scholar
  68. A. Beric, “Central pain and dysesthesia syndrome,” Neurologic Clinics, vol. 16, no. 4, pp. 899–918, 1998. View at: Publisher Site | Google Scholar
  69. J. Boivie, “Central pain,” in Textbook of Pain, P. D. Wall and R. Melzack, Eds., pp. 879–914, Churchill Livingstone, New York, NY, USA, 1999. View at: Google Scholar
  70. B. C. Hans, W. D. Willis, and C. E. Hulsebosch, “Temporal plasticity of dorsal horn somatosensory neurons after acute and chronic spinal cord hemisection in rat,” Brain Research, vol. 970, no. 1-2, pp. 238–241, 2003. View at: Publisher Site | Google Scholar
  71. D. M. Ehde, T. L. Osborne, and M. P. Jensen, “Chronic pain in persons with multiple sclerosis,” Physical Medicine and Rehabilitation Clinics of North America, vol. 16, no. 2, pp. 503–512, 2005. View at: Publisher Site | Google Scholar
  72. F. Khan and J. Pallant, “Multiple sclerosis: the prevalence of chronic pain—related disability and psychological factors impacting quality of life in an Australian community cohort,” Journal of Pain, vol. 8, no. 8, pp. 14–23, 2007. View at: Google Scholar
  73. C. J. Archibald, P. J. McGrath, P. G. Ritvo et al., “Pain prevalence, severity and impact in a clinic sample of multiple sclerosis patients,” Pain, vol. 58, no. 1, pp. 89–93, 1994. View at: Publisher Site | Google Scholar
  74. F. Khan, J. F. Pallant, B. Amatya et al., “Cognitive-behavioral classifications of chronic pain in patients with multiple sclerosis,” International Journal of Rehabilitation Research, vol. 34, no. 3, pp. 235–242, 2011. View at: Publisher Site | Google Scholar
  75. A. Burke-Doe, “Pain management,” in Neurological Rehabilitation, D. A. Umphred, Ed., Mosby Elsivier, St Louis, Mo, USA, 5th edition, 2007. View at: Google Scholar
  76. M. K. Houtchens, J. R. Richert, A. Sami, and J. W. Rose, “Open label gabapentin treatment for pain in multiple sclerosis,” Multiple Sclerosis, vol. 3, no. 4, pp. 250–253, 1997. View at: Google Scholar
  77. J. Al Smadi, C. Campbell, L. Nicholl et al., “A pilot investigation of the hypoalgesic effects of transcutaeous electrical stimulation upon lower back in people with multiple sclerosis,” Clinical Rehabilitation, vol. 17, no. 7, pp. 742–749, 2003. View at: Google Scholar
  78. L. Frighetto, A. A. de Salles, Z. A. Smith, B. Goss, M. Selch, and T. Solberg, “Noninvasive linear accelerator radiosurgery as the primary treatment for trigeminal neuralgia,” Neurology, vol. 62, no. 4, pp. 660–662, 2004. View at: Google Scholar
  79. D. J. Rog, T. J. Nurmikko, T. Friede, and C. A. Young, “Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis,” Neurology, vol. 65, no. 6, pp. 812–819, 2005. View at: Publisher Site | Google Scholar
  80. C. Solaro, M. Boehmker, and P. Tanganelli, “Pregabalin for treating paroxysmal painful symptoms in multiple sclerosis,” Journal of Neurology, vol. 256, no. 10, pp. 1773–1774, 2009. View at: Publisher Site | Google Scholar
  81. P. Gray, “Pregabalin in the management of central neuropathic pain,” Expert Opinion on Pharmacotherapy, vol. 8, no. 17, pp. 3037–3041, 2007. View at: Publisher Site | Google Scholar
  82. R. K. Heaton, “Neoropsychologicl findings in relapsing—remitting and chronic progressivd multiple sclerosis,” Journal of Consulting and Clinical Psychology, vol. 53, no. 1, pp. 103–110, 1985. View at: Publisher Site | Google Scholar
  83. S. M. Rao, G. J. Leo, L. Bernardin, and F. Unverzagt, “Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction,” Neurology, vol. 41, no. 5, pp. 685–691, 1991. View at: Google Scholar
  84. M. Pepping and D. M. Ehde, “Neuropsychological evaluation and treatment of multiple sclerosis: the importance of a neuro-rehabilitation focus,” Physical Medicine and Rehabilitation Clinics of North America, vol. 16, no. 2, pp. 411–436, 2005. View at: Publisher Site | Google Scholar
  85. D. Frankel, “Multiple sclerosis,” in Neurological Rehabilitation, D. A. Umphred, Ed., pp. 709–731, Mosby Elsievier, St Louis, Mo, USA, 5th edition, 2007. View at: Google Scholar
  86. G. M. Franklin, L. M. Nelson, C. M. Filley, and R. K. Heaton, “Cognitive loss in multiple sclerosis,” Archives of Neurology, vol. 46, no. 2, pp. 162–169, 1989. View at: Google Scholar
  87. Y. Goverover, M. Basso, H. Wood et al., “Examining the benefits of combining two learning strategies on recall of functional information in persons with multiple sclerosis,” Multiple Sclerosis. In press. View at: Publisher Site | Google Scholar
  88. A. M. Plohmann, L. Kappos, W. Ammann et al., “Computer assisted retraining of attentional impairments in patients with multiple sclerosis,” Journal of Neurology Neurosurgery and Psychiatry, vol. 64, no. 4, pp. 455–462, 1998. View at: Google Scholar
  89. M. W. Geisler, M. Sliwinski, P. K. Coyle, D. M. Masur, C. Doscher, and L. B. Krupp, “The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis,” Archives of Neurology, vol. 53, no. 2, pp. 185–188, 1996. View at: Google Scholar
  90. A. Weinstein, S. R. Schwid, R. B. Schiffer, M. P. McDermott, D. W. Giang, and A. D. Goodman, “Neuropsychologic status in multiple sclerosis after treatment with glatiramer actetate (Copaxone),” Archives of Neurology, vol. 56, no. 3, pp. 319–324, 1999. View at: Google Scholar
  91. J. F. Lovera, E. Frohman, T. R. Brown et al., “Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial,” Multiple Sclerosis, vol. 16, no. 6, pp. 713–723, 2010. View at: Publisher Site | Google Scholar
  92. L. B. Krupp, C. Christodoulou, P. Melville et al., “Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis,” Neurology, vol. 76, no. 17, pp. 1500–1507, 2011. View at: Publisher Site | Google Scholar
  93. K. Aronson, E. Goldenberg, and G. Cleghorn, “Sociodemographic characteristics and health status of persons with multiple sclerosis and their caregivers,” MS Management, vol. 3, no. 1, pp. 5–15, 1996. View at: Google Scholar
  94. M. Starck, H. Albrecht, W. Pöllmann, A. Straube, and M. Dieterich, “Drug therapy for acquired pendular nystagmus in multiple sclerosis,” Journal of Neurology, vol. 244, no. 1, pp. 9–16, 1997. View at: Google Scholar
  95. R. M. Merson and M. I. Rolnick, “Speech-language pathology and dysphagia in multiple sclerosis,” Physical Medicine and Rehabilitation Clinics of North America, vol. 9, no. 3, pp. 63–71, 1998. View at: Google Scholar
  96. S. Sapir, A. A. Pawlas, L. O. Ramig, E. Seeley, C. Fox, and J. Corboy, “Effects of intensive phonatory-respiratory treatment (LSVT) on voice in two individuals with multiple sclerosis,” Journal of Medical Speech-Language Pathology, vol. 9, no. 2, pp. 141–151, 2001. View at: Google Scholar
  97. L. Hartelius and L. Nord, “Speech modification in dysarthria associated with multiple sclerosis: an intervention based on vocal efficiency, contrastive stress, and verbal repair strategies,” Journal of Medical Speech-Language Pathology, vol. 5, no. 2, pp. 113–140, 1997. View at: Google Scholar
  98. F. J. Thomas and C. M. Wiles, “Dysphagia and nutritional status in multiple sclerosis,” Journal of Neurology, vol. 246, no. 8, pp. 677–682, 1999. View at: Publisher Site | Google Scholar
  99. P. Calcagno, G. Ruoppolo, M. G. Grasso, M. de Vincentiis, and S. Paolucci, “Dysphagia in multiple sclerosis—prevalence and prognostic factors,” Acta Neurologica Scandinavica, vol. 105, no. 1, pp. 40–43, 2002. View at: Publisher Site | Google Scholar
  100. A. de Pauw, E. Dejaeger, B. D'hooghe, and H. Carton, “Dysphagia in multiple sclerosis,” Clinical Neurology and Neurosurgery, vol. 104, no. 4, pp. 345–351, 2002. View at: Publisher Site | Google Scholar
  101. S. B. Patten, C. A. Beck, J. V. A. Williams, C. Barbui, and L. M. Metz, “Major depression in multiple sclerosis: a population-based perspective,” Neurology, vol. 61, no. 11, pp. 1524–1527, 2003. View at: Google Scholar
  102. W. Katon and P. Ciechanowski, “Impact of major depression on chronic medical illness,” Journal of Psychosomatic Research, vol. 53, no. 4, pp. 859–863, 2002. View at: Publisher Site | Google Scholar
  103. R. H. B. Benedict, J. S. Fischer, C. J. Archibald et al., “Minimal neuropsychological assessment of MS patients: a consensus approach,” Clinical Neuropsychologist, vol. 16, no. 3, pp. 381–397, 2002. View at: Publisher Site | Google Scholar
  104. D. C. Mohr, A. C. Boudewn, D. E. Goodin et al., “Comparative outcomes for individual cognitive behaviour therapy, supportive espressive group psychotherapy, and setraline for the treatment of depression in multiple sclerosis,” Journal of Consulting and Clinical Psychology, vol. 69, no. 6, pp. 942–949, 2001. View at: Google Scholar
  105. D. C. Mohr, W. Likosky, A. Bertagnolli et al., “Telephone-administered cognitive-behavioral therapy for the treatment of depressive symptoms in multiple sclerosis,” Journal of Consulting and Clinical Psychology, vol. 68, no. 2, pp. 356–361, 2000. View at: Publisher Site | Google Scholar
  106. A. L. Brosse, E. S. Sheets, H. S. Lett, and J. A. Blumenthal, “Exercise and the treatment of clinical depression in adults: recent findings and future directions,” Sports Medicine, vol. 32, no. 12, pp. 741–760, 2002. View at: Google Scholar
  107. E. W. Martinsen, “Physical activity and depression: clinical experience,” Acta Psychiatrica Scandinavica, vol. 377, pp. 23–27, 1994. View at: Google Scholar
  108. D. R. Hopko, C. W. Lejuez, K. J. Ruggiero, and G. H. Eifert, “Contemporary behavioral activation treatments for depression: procedures, principles, and progress,” Clinical Psychology Review, vol. 23, no. 5, pp. 699–717, 2003. View at: Publisher Site | Google Scholar
  109. G. L. Klerman and M. M. Weissmann, “Interpersonal psychotherapy (IPT) and drugs in the treatment of depression,” Pharmacopsychiatry, vol. 20, no. 1, pp. 3–7, 1987. View at: Google Scholar
  110. F. Khan, J. Pallant, and C. Brand, “Caregiver strain and factors associated with caregiver self-efficacy and quality of life in a community cohort with multiple sclerosis,” Disability and Rehabilitation, vol. 29, no. 16, pp. 1241–1260, 2007. View at: Publisher Site | Google Scholar
  111. R. H. B. Benedict, A. Shapiro, R. Priore, C. Miller, F. Munschauer, and L. Jacobs, “Neuropsychological counseling improves social behavior in cognitively-impaired multiple sclerosis patients,” Multiple Sclerosis, vol. 6, no. 6, pp. 391–396, 2000. View at: Publisher Site | Google Scholar
  112. T. R. Brown and G. H. Kraft, “Exercise and rehabilitation for individuals with multiple sclerosis,” Physical Medicine and Rehabilitation Clinics of North America, vol. 16, no. 2, pp. 513–556, 2005. View at: Publisher Site | Google Scholar
  113. A. T. White, “Exercise and MS: challenges and opportunities,” Multiple Sclerosis Quality Report, vol. 23, no. 1, pp. 18–20, 2004. View at: Google Scholar
  114. D. C. Hewson, M. A. Phillips, K. E. Simpson, P. Drury, and M. A. Crawford, “Food intake in multiple sclerosis,” Human Nutrition. Applied nutrition, vol. 38, no. 5, pp. 355–367, 1984. View at: Google Scholar
  115. G. H. Kraft, “Foreword,” Physical Medicine and Rehabilitation Clinics of North America, vol. 9, no. 3, pp. 11–13, 1998. View at: Google Scholar
  116. M. L. Aisen, A. Arnold, I. Baiges, S. Maxwell, and M. Rosen, “The effect of mechanical damping loads on disabling action tremor,” Neurology, vol. 43, no. 7, pp. 1346–1350, 1993. View at: Google Scholar
  117. M. M. LaBan, T. Martin, J. Pechur, and S. Sarnacki, “Physical and occupational therapy in the treatment of patients with multiple sclerosis,” Physical Medicine and Rehabilitation Clinics of North America, vol. 9, no. 3, pp. 603–614, 1998. View at: Google Scholar
  118. H. Bronnum-Hansen, H. Hansen, N. Kock-Henriksen, and E. Stenager, “Fatal accidents among Danes with multiple sclerosis,” Multiple Sclerosis, vol. 12, pp. 329–332, 2006. View at: Google Scholar
  119. M. T. Schulthesis, E. Garay, S. R. Millis, and J. DeLuca, “Motor vehicle crashes and violations among drivers with multiple sclerosis,” Archives of Physical Medicine and Rehabilitation, vol. 83, no. 8, pp. 1175–1178, 2002. View at: Publisher Site | Google Scholar
  120. P. Rumrill, Employment Issues and Multiple Sclerosis, Demos Publications, New York, NY, USA, 1996.
  121. K. L. Johnson and R. T. Fraser, “Mitigating the impact of multiple sclerosis on employment,” Physical Medicine and Rehabilitation Clinics of North America, vol. 16, no. 2, pp. 771–783, 2005. View at: Publisher Site | Google Scholar
  122. F. Khan, L. Ng, and L. Turner-Stokes, “Effectiveness of vocational rehabilitation intervention on the return to work and employment of persons with multiple sclerosis,” The Cochrane Database of Systematic Reviews, no. 1, Article ID CD007256, 2009. View at: Google Scholar

Copyright © 2011 Fary Khan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

5760 Views | 1528 Downloads | 19 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.